RMD

ResMed Inc. (RMD) | Rumor.io

ResMed

RMD

Attention (50-day avg)0.01%

Attention rank (50-day avg)#430

Bullish sentiment (50-day avg)83%

Price to earnings ratio21.1

Market capitalization32B

Earnings per share10.4

Dividend yield (TTM)1.19%

Revenue (annual)5.7B

Net income (annual)1.5B

Social

What share of all stock conversation is about RMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% -0.02	0% -0.01	0% 0

Sep 21

RMD has decreased by 3.2% in the past 11 days.

Generated by AI

Sentiment

Of the messages about RMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	85.71% +3.57	68.5% -22.57
Bearish	—	—	14.29% -3.57	31.5% +22.57

Bullish· Jul 31

ResMed Inc. ($RMD) has a history of announcing acquisitions during quarterly meetings, which could benefit both companies and help the drug get to market faster.
The company's recent Phase 2 completion results, which exceeded expectations, create an ideal time for $RMD to invest in IXHL, especially with a member on IXHL's advisory board since February.
A partnership or investment from $RMD could significantly benefit IXHL, potentially leading to a rerating of the share price to $7-$12 per share.

Bearish· Jun 24

ResMed Inc. ($RMD) may face reduced demand for its CPAP devices due to weight loss drugs that can reduce sleep apnea severity.
ResMed stock fell after a ratings downgrade from Citigroup, with a price target reduced to Neutral from Buy.
The company's stock price has declined by over 10% in the pre-market, with some analysts predicting further downside due to the impact of GLP-1 uptake on the market.

Generated by AI

Topics

Of the messages about RMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	37.21%	3.09%
Macro	—	—	13.95%	31.72%
Technical Analysis	—	—	0%	31.43%
Analysts	—	—	48.84%	31.45%
Earnings	—	—	0%	2.28%
Controversies	—	—	0%	0.03%

Earnings· Oct 25

ResMed Inc. ($RMD) reported Q1 non-GAAP EPS of $0.81, beating estimates by $0.03.
Revenue of $588.28M for Q1 was $13.95M above expectations, representing a 12.3% year-over-year increase.
ResMed's Q1 earnings of 81c EPS and $588.28M in revenue met or exceeded various consensus estimates.

Analysts· Jan 24

JPMorgan analyst David Low upgrades ResMed to Overweight with a raised price target from $260 to $270.
Bank of America upgrades ResMed to Neutral with a raised price target from $239 to $250.
JPMorgan upgrades ResMed to Overweight from Neutral, citing a "year of opportunity" ahead.

Announcements· Jun 14

ResMed Inc. ($RMD) has agreed to acquire MEDIFOX DAN, a German leader in out-of-hospital software solutions, for approximately $1 billion.
The acquisition is expected to be accretive to ResMed's non-GAAP diluted earnings per share after close.
ResMed will fund the acquisition with its existing credit facilities, and the transaction is expected to be completed soon.

Macro· Jan 6

The Secure Act 2.0 aims to increase retirement savings, potentially benefiting the government by keeping more money in the market.
The law's provisions, including increased catch-up limits and mandatory 401(k) enrollment, may lead to increased market value and savings.
The government's goal is to encourage more people to save for retirement, which could help prop up the markets as Baby Boomers withdraw from retirement accounts.

Technical Analysis· Jan 25

$RMD is considered overreacted, presenting a long-term buying opportunity.
Technical analysis signals, including MACD crosses and buy signals, indicate potential short-term bounces around $96-$98 or $100.
Strong support levels are identified at $92.89 and $92.86, with a trend line below which the stock should not go.

Generated by AI

Community

Of the messages about RMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	22.5%	3.21%	15.55%
Newcomers	100%	77.5%	96.79%	84.45%

Regulars· Apr 30

ResMed's Q3 2026 results beat expectations, with revenue increasing 11% to $1.43 billion and EPS surging 20% to $2.86.
The company's gross margin expanded by 290 basis points to 62.2% (62.8% non-GAAP), driving a 17% increase in GAAP income from operations and an 18% increase in non-GAAP income from operations.
ResMed's Q3 performance was marked by a slight decline in share price, with the stock down 5% in the US session, despite the company's robust earnings beat and leadership change, with CFO Brett Sandercock to retire and Aaron Bloomer appointed as successor.

Newcomers· Sep 21

The newcomer is discussing the recent decline in ResMed Inc.'s stock price, specifically mentioning a 3.2% drop over 11 days.
The newcomer is sharing their trading record, which shows a 156-58 win-loss ratio, and is asking for advice on managing losing trades.
The newcomer is not explicitly discussing the company's fundamentals or any specific news related to ResMed Inc.

Generated by AI

News

Is ResMed A Better Way Than Stryker To Own Medical Device Growth?

1d agoYahoo Finance

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

8d agoYahoo Finance

ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures

11d agoYahoo Finance

Also Discussed

Investors talking about RMD also mention

#	Name	Attention
1	STERIS plcSTE	0%0
2	Inspire Medical Systems, Inc.INSP	0.01%new
3	Carlisle Cos IncCSL	0%new
4	Nyxoah SANYXH	0%new
5	Northfield Bancorp Inc.NFBK	0%0
6	Southern First Bancshares, Inc.SFST	0%new
7	LivaNova PLCLIVN	0%0
8	Koninklijke Philips N.V. ADRPHG	0%0
9	Five Point Holdings LLC Class A Common SharesFPH	0%new
10	West Bancorporation Inc.WTBA	0%0

ResMed Inc.

Healthcare
Medical Instruments & Supplies

ResMed Inc. is a healthcare company that develops and supplies digital health technologies and cloud-connected medical devices for respiratory care. Its core products support the treatment of sleep apnea, COPD, and other chronic diseases through flow generators, masks, and related accessories used in home-based and clinical settings. ResMed also provides software and data platforms that help clinicians, patients, and care providers monitor therapy and manage ongoing treatment more effectively. The company serves healthcare systems, medical professionals, and patients across multiple regions, with a strong presence in the Americas as well as Europe, Japan, and Australia. Headquartered in San Diego, California, ResMed plays an important role in the medical instruments and supplies market by combining device-based therapy with connected digital care solutions.

Website

Location

9001 Spectrum Center Boulevard

San Diego, CA, 92123

United States

Social

What share of all stock conversation is about RMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% -0.02	0% -0.01	0% 0

Sep 21

RMD has decreased by 3.2% in the past 11 days.

Generated by AI

Sentiment

Of the messages about RMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	85.71% +3.57	68.5% -22.57
Bearish	—	—	14.29% -3.57	31.5% +22.57

Bullish· Jul 31

ResMed Inc. ($RMD) has a history of announcing acquisitions during quarterly meetings, which could benefit both companies and help the drug get to market faster.
The company's recent Phase 2 completion results, which exceeded expectations, create an ideal time for $RMD to invest in IXHL, especially with a member on IXHL's advisory board since February.
A partnership or investment from $RMD could significantly benefit IXHL, potentially leading to a rerating of the share price to $7-$12 per share.

Bearish· Jun 24

ResMed Inc. ($RMD) may face reduced demand for its CPAP devices due to weight loss drugs that can reduce sleep apnea severity.
ResMed stock fell after a ratings downgrade from Citigroup, with a price target reduced to Neutral from Buy.
The company's stock price has declined by over 10% in the pre-market, with some analysts predicting further downside due to the impact of GLP-1 uptake on the market.

Generated by AI

Topics

Of the messages about RMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	37.21%	3.09%
Macro	—	—	13.95%	31.72%
Technical Analysis	—	—	0%	31.43%
Analysts	—	—	48.84%	31.45%
Earnings	—	—	0%	2.28%
Controversies	—	—	0%	0.03%

Earnings· Oct 25

ResMed Inc. ($RMD) reported Q1 non-GAAP EPS of $0.81, beating estimates by $0.03.
Revenue of $588.28M for Q1 was $13.95M above expectations, representing a 12.3% year-over-year increase.
ResMed's Q1 earnings of 81c EPS and $588.28M in revenue met or exceeded various consensus estimates.

Analysts· Jan 24

JPMorgan analyst David Low upgrades ResMed to Overweight with a raised price target from $260 to $270.
Bank of America upgrades ResMed to Neutral with a raised price target from $239 to $250.
JPMorgan upgrades ResMed to Overweight from Neutral, citing a "year of opportunity" ahead.

Announcements· Jun 14

ResMed Inc. ($RMD) has agreed to acquire MEDIFOX DAN, a German leader in out-of-hospital software solutions, for approximately $1 billion.
The acquisition is expected to be accretive to ResMed's non-GAAP diluted earnings per share after close.
ResMed will fund the acquisition with its existing credit facilities, and the transaction is expected to be completed soon.

Macro· Jan 6

The Secure Act 2.0 aims to increase retirement savings, potentially benefiting the government by keeping more money in the market.
The law's provisions, including increased catch-up limits and mandatory 401(k) enrollment, may lead to increased market value and savings.
The government's goal is to encourage more people to save for retirement, which could help prop up the markets as Baby Boomers withdraw from retirement accounts.

Technical Analysis· Jan 25

$RMD is considered overreacted, presenting a long-term buying opportunity.
Technical analysis signals, including MACD crosses and buy signals, indicate potential short-term bounces around $96-$98 or $100.
Strong support levels are identified at $92.89 and $92.86, with a trend line below which the stock should not go.

Generated by AI

Community

Of the messages about RMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	22.5%	3.21%	15.55%
Newcomers	100%	77.5%	96.79%	84.45%

Regulars· Apr 30

ResMed's Q3 2026 results beat expectations, with revenue increasing 11% to $1.43 billion and EPS surging 20% to $2.86.
The company's gross margin expanded by 290 basis points to 62.2% (62.8% non-GAAP), driving a 17% increase in GAAP income from operations and an 18% increase in non-GAAP income from operations.
ResMed's Q3 performance was marked by a slight decline in share price, with the stock down 5% in the US session, despite the company's robust earnings beat and leadership change, with CFO Brett Sandercock to retire and Aaron Bloomer appointed as successor.

Newcomers· Sep 21

The newcomer is discussing the recent decline in ResMed Inc.'s stock price, specifically mentioning a 3.2% drop over 11 days.
The newcomer is sharing their trading record, which shows a 156-58 win-loss ratio, and is asking for advice on managing losing trades.
The newcomer is not explicitly discussing the company's fundamentals or any specific news related to ResMed Inc.

Generated by AI

ResMed

Social

Sep 21

Bullish· Jul 31

Bearish· Jun 24

Earnings· Oct 25

Analysts· Jan 24

Announcements· Jun 14

Macro· Jan 6

Technical Analysis· Jan 25

Regulars· Apr 30

Newcomers· Sep 21

Is ResMed A Better Way Than Stryker To Own Medical Device Growth?

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures

ResMed Inc. stock falls Friday, underperforms market

Why is ResMed stock rallying today?

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Also Discussed

ResMed Inc.

Company Information

Location

Is ResMed A Better Way Than Stryker To Own Medical Device Growth?

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures

ResMed Inc. stock falls Friday, underperforms market

Why is ResMed stock rallying today?

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Also Discussed

Social

Sep 21

Bullish· Jul 31

Bearish· Jun 24

Earnings· Oct 25

Analysts· Jan 24

Announcements· Jun 14

Macro· Jan 6

Technical Analysis· Jan 25

Regulars· Apr 30

Newcomers· Sep 21